Want to see CCLD full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CCLD Q2 2026 EPS Results
Actual EPS$0.00
Consensus EPS$0.02
Beat/MissMissed by -$0.02
One Year Ago EPS$0.04
CCLD Q2 2026 Revenue Results
Actual Revenue$31.88M
Expected Revenue$31.85M
Beat/MissBeat by +$29.00K
YoY Revenue Growth+16.45%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
CCLD Upcoming Earnings
CareCloud's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CCLD Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a constructive, strategic story: solid top-line growth (+16% Q2, +15% H1), a growing recurring revenue mix, continued GAAP profitability streak, a cleaner capital structure after fully redeeming Series B, and clear progress on AI and a new compliance SaaS initiative. Near-term reported profitability and some cash metrics are pressured by deliberate investment choices — accelerated R&D expense, acquisition-related amortization, and higher interest — and by integration work (notably Medsphere). Management reaffirmed guidance and expects a stronger second half as investments convert to scale. Overall, positives (revenue/regional trends, recurring revenue expansion, capital structure improvement, AI/product milestones, new market entry) outweigh the near-term headwinds driven by strategic investments and integration costs, but execution risk remains.Company Guidance
Revenue Growth and Recurring Revenue Expansion
Q2 revenue was $31.9M, up 16% YoY (from $27.4M); first half revenue was $63.2M, up 15% YoY (from $55.0M). Recurring technology-enabled revenue represented ~75% of Q2 revenue (up from 69% a year ago, +6 percentage points) with recurring revenue of ~$24M in the quarter (approximately +$5M YoY, roughly +26%).
Sustained GAAP Profitability and Cash Generation
Ninth consecutive quarter of GAAP net income (Q2 GAAP net income $1.1M). Q2 adjusted EBITDA was $5.9M. Q2 free cash flow was $5.7M (+~5.6% YoY) and the company generated $8.1M of free cash flow year-to-date.
Cleaned-Up Capital Structure
Redeemed 100% of Series B preferred stock on May 15 using a $50M credit facility (zero dilution). This eliminates approximately $3.3M of annual preferred dividends and is expected to increase cash flow available to common shareholders; new $50M facility is lower cost and the company established a $60M at-the-market equity program.
Acquisition: Entry into Compliance and Audit Defense
Acquired Empower Healthcare and Compliance Partners in May (funded from operating cash flow), expanding CareCloud into compliance/audit defense. Early win: Empower helped reverse >$1M in alleged overpayments for a client in June. Plan to convert Empower's expertise into an AI-enabled compliance SaaS (tiered subscription) in fall 2026 to drive recurring revenue and cross-sell opportunities.
Meaningful AI and Product Progress
AI initiatives advancing: prior authorization and AI-assisted medical coding on track for market this year (pilots/internal runs); stratusAI Front Desk demand strong with new deals in implementation. Platform milestones delivered: parity on Inpatient RCM Cloud, CareVue parity items complete, Wellsoft integrations live (Breeze and cirrusAI notes), Marketware added integrations (PracticeMatch, DocCafe) and an AI candidate-matching engine. Management reports visible, measurable progress across internal efficiency, embedded product AI, and new AI offerings.
Reaffirmed Full-Year Guidance
Company reaffirmed FY2026 guidance: revenue $128M–$132M, adjusted EBITDA $29M–$31M, GAAP EPS $0.20–$0.23, implying stronger second-half performance relative to the first half.
CCLD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed